Received Feb 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 1 | — | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
No additional AE; On 22Jan2025 received SHINGRIX. On 03Feb2025 patient came in an they administered the VARIVAX.; On 22Jan2025 she was scheduled to get VARIVAX/ instead inadvertently received SHINGRIX; This spontaneous report has been received from a nurse concerning to a 33-year-old female patient. The patient's pertinent medical history, concurrent conditions, drugs reactions or allergies and concomitant medications were not provided by the reporter. It was reported that the patient needed to get varicella virus vaccine live (Oka/Merck) (VARIVAX) for her nursing school. On 22-JAN-2025, she was scheduled to get varicella virus vaccine live (Oka/Merck) (VARIVAX) but instead inadvertently received varicella zoster vaccine rge (cho) (SHINGRIX) as prophylaxis (formulation, strength, dose, route and anatomical location of administration, lot #, and expiration date were not provided) (wrong product administered). Later, on 03-FEB-2025 (reported as today) the patient was vaccinated with the first dose of varicella virus vaccine live (Oka/Merck) (VARIVAX) injection (strength, dose, route and anatomical location of administration, lot #, and expiration date were not provided) as prophylaxis (extra dose administered). No other information was known or reported. No side effects and no additional adverse event (AE) were reported. Lot # is being requested and will be submitted if received.
Prophylaxis